{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:48Z","timestamp":1793734248336,"version":"4.6.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,12]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>NRAS and KRAS mutations lead to different downstream transcriptional signatures and patient prognoses under current myeloma therapies. RAS genotype alone does not strongly predict degree of active MAPK signaling, suggesting alternate precision medicine approaches are needed.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000303","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T11:32:17Z","timestamp":1572348737000},"page":"3214-3227","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-4330","authenticated-orcid":false,"given":"Yu-Hsiu T.","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-9348","authenticated-orcid":false,"given":"Gregory P.","family":"Way","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarette C.","family":"Mariano","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makeba","family":"Marcoulis","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-8762","authenticated-orcid":false,"given":"Ian D.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[{"name":"Experimental Oncology and Hematology, Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-9213","authenticated-orcid":false,"given":"Casey S.","family":"Greene","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA;"},{"name":"Childhood Cancer Data Laboratory, Alex\u2019s Lemonade Stand Foundation, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"issue":"1","key":"2019111523112735800_B1","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"7339","key":"2019111523112735800_B2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2019111523112735800_B3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/leu.2017.197","article-title":"Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma","volume":"32","author":"Lagan\u00e0","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2019111523112735800_B4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111523112735800_B5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019111523112735800_B6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41375-018-0362-z","article-title":"The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies","volume":"33","author":"Harding","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2019111523112735800_B7","doi-asserted-by":"crossref","first-page":"1600235","DOI":"10.1002\/pmic.201600235","article-title":"Impact of phosphoproteomics in the translation of kinase-targeted therapies","volume":"17","author":"Casado","year":"2017","journal-title":"Proteomics"},{"issue":"3","key":"2019111523112735800_B8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/14789450.2014.901156","article-title":"Proteomic analysis of phosphorylation in cancer","volume":"11","author":"Ruprecht","year":"2014","journal-title":"Expert Rev Proteomics"},{"issue":"4","key":"2019111523112735800_B9","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/gb-2013-14-4-r37","article-title":"Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors","volume":"14","author":"Casado","year":"2013","journal-title":"Genome Biol"},{"issue":"8","key":"2019111523112735800_B10","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","article-title":"Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells","volume":"32","author":"Casado","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"2019111523112735800_B11","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/1873-3468.12748","article-title":"Approaches to identify kinase dependencies in cancer signalling networks","volume":"591","author":"Dermit","year":"2017","journal-title":"FEBS Lett"},{"key":"2019111523112735800_B12","first-page":"81","article-title":"Targeting RAS directly","volume":"2","author":"McCormick","year":"2018","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"2019111523112735800_B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"11","key":"2019111523112735800_B14","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"2019111523112735800_B15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2019111523112735800_B16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1042\/BST20140057","article-title":"Decoding RAS isoform and codon-specific signalling","volume":"42","author":"Newlaczyl","year":"2014","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"2019111523112735800_B17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111523112735800_B18","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"88","author":"Liu","year":"1996","journal-title":"Blood"},{"issue":"12","key":"2019111523112735800_B19","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2019111523112735800_B20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111523112735800_B21","first-page":"2268","article-title":"Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6","volume":"57","author":"Billadeau","year":"1997","journal-title":"Cancer Res"},{"issue":"57","key":"2019111523112735800_B22","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1038\/sj.onc.1205387","article-title":"Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response","volume":"21","author":"Rowley","year":"2002","journal-title":"Oncogene"},{"issue":"5","key":"2019111523112735800_B23","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"issue":"7","key":"2019111523112735800_B24","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3324\/haematol.2017.174482","article-title":"Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment","volume":"103","author":"Lam","year":"2018","journal-title":"Haematologica"},{"key":"2019111523112735800_B25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.celrep.2018.03.046","article-title":"Machine learning detects pan-cancer ras pathway activation in the cancer genome atlas","volume":"23","author":"Way","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"2019111523112735800_B26","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"2019111523112735800_B27","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","volume":"30","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"issue":"268","key":"2019111523112735800_B28","doi-asserted-by":"crossref","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","article-title":"Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells","volume":"6","author":"Casado","year":"2013","journal-title":"Sci Signal"},{"issue":"12","key":"2019111523112735800_B29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2019111523112735800_B30","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/leu.2016.264","article-title":"Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS","volume":"31","author":"M\u00fcller","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2019111523112735800_B31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/1078-0432.CCR-13-1943","article-title":"Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients","volume":"20","author":"Guinney","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111523112735800_B32","doi-asserted-by":"crossref","first-page":"e0185862","DOI":"10.1371\/journal.pone.0185862","article-title":"Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors [published correction appears in PLoS One. 2018;13(1):e0192059]","volume":"12","author":"Merchant","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"2019111523112735800_B33","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2003-04-1227","article-title":"Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells","volume":"102","author":"Croonquist","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2019111523112735800_B34","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/2159-8290.CD-13-0096","article-title":"Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation","volume":"3","author":"Xu","year":"2013","journal-title":"Cancer Discov"},{"key":"2019111523112735800_B35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"6","key":"2019111523112735800_B36","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood-2010-05-284422","article-title":"Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival","volume":"117","author":"Steinbrunn","year":"2011","journal-title":"Blood"},{"issue":"33","key":"2019111523112735800_B37","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111523112735800_B38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"2019111523112735800_B39","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies","volume":"2","author":"Kalff","year":"2012","journal-title":"Blood Cancer J"},{"issue":"2","key":"2019111523112735800_B40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med Res Rev"},{"issue":"Database issue","key":"2019111523112735800_B41","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2019111523112735800_B42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.24300","article-title":"TAK-228 (formerly MLN0128), an investigational oral dual TORC1\/2 inhibitor: a phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"91","author":"Ghobrial","year":"2016","journal-title":"Am J Hematol"},{"issue":"7606","key":"2019111523112735800_B43","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"issue":"565","key":"2019111523112735800_B44","doi-asserted-by":"crossref","first-page":"eaau8645","DOI":"10.1126\/scisignal.aau8645","article-title":"Illuminating the dark phosphoproteome","volume":"12","author":"Needham","year":"2019","journal-title":"Sci Signal"},{"issue":"4","key":"2019111523112735800_B45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.12039","article-title":"Combined targeting of MEK\/MAPK and PI3K\/Akt signalling in multiple myeloma","volume":"159","author":"Steinbrunn","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111523112735800_B46","doi-asserted-by":"crossref","first-page":"13522","DOI":"10.1038\/s41598-018-31820-9","article-title":"Frequent functional activation of RAS signalling not explained by RAS\/RAF mutations in relapsed\/refractory multiple myeloma","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"key":"2019111523112735800_B47","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cell.2017.01.020","article-title":"KRAS allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer","volume":"168","author":"Burgess","year":"2017","journal-title":"Cell"},{"key":"2019111523112735800_B48","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ccell.2018.10.003","article-title":"Widespread selection for oncogenic mutant allele imbalance in cancer","volume":"34","author":"Bielski","year":"2018","journal-title":"Cancer Cell"},{"issue":"14","key":"2019111523112735800_B49","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019111523112735800_B50","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-14-0729","article-title":"Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma","volume":"4","author":"Burd","year":"2014","journal-title":"Cancer Discov"},{"issue":"16","key":"2019111523112735800_B51","first-page":"3640","article-title":"Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6","volume":"55","author":"Billadeau","year":"1995","journal-title":"Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/21\/3214\/1506242\/advancesadv2019000303.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/21\/3214\/1506242\/advancesadv2019000303.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:21:07Z","timestamp":1573863667000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/21\/3214\/422647\/Integrated-phosphoproteomics-and-transcriptional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":51,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000303","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/563312","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]}}}